M
Mark Hertzberg
Researcher at University of New South Wales
Publications - 124
Citations - 3751
Mark Hertzberg is an academic researcher from University of New South Wales. The author has contributed to research in topics: Transplantation & Diffuse large B-cell lymphoma. The author has an hindex of 28, co-authored 118 publications receiving 2972 citations. Previous affiliations of Mark Hertzberg include Westmead Hospital & Royal Melbourne Hospital.
Papers
More filters
Journal ArticleDOI
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
Ian W. Flinn,Richard van der Jagt,Brad S. Kahl,Peter Wood,Tim E. Hawkins,David MacDonald,Mark Hertzberg,Yiu Lam Kwan,David Simpson,Michael Craig,Kathryn S. Kolibaba,Samar Issa,Regina Clementi,Doreen M. Hallman,Mihaela C. Munteanu,Ling Chen,John M. Burke +16 more
TL;DR: Data indicate BR is noninferior to standard therapy with regard to clinical response with an acceptable safety profile, and this trial was registered at www.clinicaltrials.gov as #NCT00877006.
Journal ArticleDOI
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Laurie H. Sehn,Alex F. Herrera,Christopher R. Flowers,Manali Kamdar,Andrew McMillan,Mark Hertzberg,Sarit Assouline,Tae Min Kim,Won Seog Kim,Muhit Ozcan,Jamie Hirata,Elicia Penuel,Joseph N. Paulson,Ji Cheng,Grace Ku,Matthew J. Matasar +15 more
TL;DR: Polatuzumab vedotin combined with BR resulted in a significantly higher CR rate and reduced the risk of death by 58% compared with BR in patients with transplantation-ineligible R/R DLBCL.
Journal ArticleDOI
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing
David M. Kurtz,Michael R. Green,Scott V. Bratman,Florian Scherer,Chih Long Liu,Christian A. Kunder,Kazuhiro Takahashi,Cynthia Glover,Colm Keane,Shingo Kihira,Brendan C. Visser,Jason Callahan,Katherine A. Kong,Malek Faham,Karen S. Corbelli,David B. Miklos,Ranjana H. Advani,Ronald Levy,Rodney J. Hicks,Mark Hertzberg,Robert S. Ohgami,Maher K. Gandhi,Maher K. Gandhi,Maximilian Diehn,Ash A. Alizadeh +24 more
TL;DR: Given its high specificity, Ig-HTS from plasma has potential clinical utility for surveillance after complete remission in patients initially achieving remission of diffuse large B-cell lymphoma.
Journal ArticleDOI
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
Frank Vari,David Arpon,Colm Keane,Colm Keane,Mark Hertzberg,Dipti Talaulikar,Dipti Talaulikar,Sanjiv Jain,Qingyan Cui,Erica Han,Josh Tobin,Josh Tobin,Robert Bird,Donna Cross,Annette Hernandez,Clare Gould,Clare Gould,Simone Birch,Maher K. Gandhi,Maher K. Gandhi +19 more
TL;DR: A hitherto unrecognized immune evasion strategy mediated via skewing toward an exhausted PD-1-enriched CD3-CD56hiCD16-ve NK-cell phenotype is described, which can occur indirectly by PD-L1/PD-L2-expressing TAMs and contribute to the clinical sensitivity of cHL toPD-1 blockade.
Journal ArticleDOI
Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
Biju George,Nalini K Pati,Nicole Gilroy,M Ratnamohan,Gillian Huang,Ian Kerridge,Mark Hertzberg,David Gottlieb,Kenneth F. Bradstock +8 more
TL;DR: Pre‐transplant cytomegalovirus serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.